Aptevo Therapeutics

100 articles about Aptevo Therapeutics

• Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

  4/15/2024

  Aptevo Therapeutics Inc. (NASDAQ:APVO) today announced the closing of its previously announced public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock (the "Common Warrants") at a purchase price of $1.35 per share and associated Common Warrant.

• Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

  4/11/2024

  Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.

• Aptevo Therapeutics Provides Pipeline Update

  4/10/2024

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.

• Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

  3/18/2024

  Aptevo Therapeutics Inc. announced that the Company is participating in The Springtime Event, a Bio-Europe conference occurring March 18-20, 2024 in Barcelona, Spain.

• Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

  3/7/2024

  Alligator Bioscience AB and Aptevo Therapeutics today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4.

• Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

  3/5/2024

  Aptevo Therapeutics Inc. today reported financial results for the year ended December 31, 2023 and provided a business update.

• Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

  3/4/2024

  Aptevo Therapeutics Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-44.

• Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

  11/14/2023

  Aptevo Therapeutics Inc. today reported financial results for the quarter ended September 30, 2023 and provided a business update.

• Aptevo to Present at Bio-Europe Conference

  11/1/2023

  Aptevo Therapeutics Inc. today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany.

• Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

  8/10/2023

  Aptevo Therapeutics Inc. today reported financial results for the quarter ended June 30, 2023 and provided a business update, including duration of remission (DOR) data for its lead clinical candidate, APVO436.

• Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

  8/4/2023

  Aptevo Therapeutics Inc. announced the closing of its previously announced public offering of 2,221,550 shares of common stock at a purchase price of $0.62 per share, Pre-Funded Warrants to purchase up to an aggregate of 5,842,967 shares of common stock at a purchase price of $0.619 per Pre-Funded Warrant.

• Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

  8/1/2023

  Aptevo Therapeutics Inc. announced that the Company has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 8,064,517 shares of common stock at a purchase price of $0.62 per share.

• Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

  7/18/2023

  Aptevo Therapeutics Inc. today announced that its bispecific AML drug candidate APVO436, in combination with emerging standard of care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose escalation trial.

• Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

  5/11/2023

  Aptevo Therapeutics Inc. today reported financial results for the quarter ended March 31, 2023 and provided a business update.

• Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

  3/30/2023

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the year ended December 31, 2022 and business highlights.

• Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

  3/30/2023

  Aptevo Therapeutics Inc. announced that the Company has raised $9.6 million in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50,000 possible based on IXINITY sales in Q123.

• Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

  2/13/2023

  Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of the first patient in the companies' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4.

• Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

  1/9/2023

  Aptevo Therapeutics Inc. today announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon.

• 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

  12/12/2022

  Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naive.

• Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

  9/19/2022

  Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.